- $51.38m
- $2.53m
- $0.40m
- 30
- 23
- 43
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.92 | ||
| Price to Tang. Book | 1.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 102.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.19% | ||
| Return on Equity | -54.5% | ||
| Operating Margin | -4089.4% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.37 | 1.88 | n/a | 0.23 | 0.4 | 0.2 | 0.17 | -24.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.
Directors
- Thomas Isett CHM (56)
- Robert Lutz CFO (52)
- Randy Maddux COO (60)
- Martin Brenner CSO (51)
- Linda Armstrong IND (58)
- Glenn Chang IND (73)
- William Clark IND (53)
- James Hill IND (75)
- Alexandra Kropotova IND (49)
- John McKey IND (78)
- Evert Schimmelpennink IND (49)
- Gary Sender IND (59)
- Last Annual
- June 30th, 2025
- Last Interim
- September 30th, 2025
- Incorporated
- April 17th, 2008
- Public Since
- August 18th, 2008
- No. of Shareholders
- 21
- No. of Employees
- 20
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 23,895,789
- Address
- 11750 Sorrento Valley Road, Suite 200, SAN DIEGO, 92121
- Web
- https://ibioinc.com/
- Phone
- +1 9794460027
- Auditors
- Grassi & Co., CPAs, P.C.
Upcoming Events for IBIO
iBio Inc at Oppenheimer Healthcare Life Sciences Conference (Virtual)
iBio Inc at Leerink Global Healthcare Conference
Q3 2026 iBio Inc Earnings Release
Similar to IBIO
ABPRO Holdings
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the iBio share price?
As of Today at 02:13 UTC, shares in iBio are trading at $2.15. This share price information is delayed by 15 minutes.
How has the iBio share price performed this year?
Shares in iBio last closed at $2.15 and the price had moved by -36.76% over the past 365 days. In terms of relative price strength the iBio share price has underperformed the S&P500 Index by -43.41% over the past year.
What are the analyst and broker recommendations for iBio?
The overall consensus recommendation for iBio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the iBio dividend yield?
iBio does not currently pay a dividend.
Does iBio pay a dividend?
iBio does not currently pay a dividend.
When does iBio next pay dividends?
iBio does not currently pay a dividend.
How do I buy iBio shares?
To buy shares in iBio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of iBio?
As of the previous close price of $2.15, shares in iBio had a market capitalisation of $51.38m.
Where are iBio shares listed?
Here are the trading details for iBio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IBIO
What kind of share is iBio?
Based on an overall assessment of its quality, value and momentum iBio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a iBio share price forecast for 2026?
The analyst consensus target price for shares in iBio is $4.52. That is 110.23% above the last closing price of $2.15.
Analysts covering iBio currently have a consensus Earnings Per Share (EPS) forecast of -$0.33 for the next financial year.
Find out moreWhat is the trend in the iBio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like iBio. Over the past six months, its share price has outperformed the S&P500 Index by +239.21%.
As of the last closing price of $2.15, shares in iBio were trading +85.66% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the iBio PE Ratio?
The iBio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of iBio?
iBio's management team is headed by:
- Thomas Isett - CHM
- Robert Lutz - CFO
- Randy Maddux - COO
- Martin Brenner - CSO
- Linda Armstrong - IND
- Glenn Chang - IND
- William Clark - IND
- James Hill - IND
- Alexandra Kropotova - IND
- John McKey - IND
- Evert Schimmelpennink - IND
- Gary Sender - IND